Abstracts tagged "Clinical practice"

Abstract Number: 1641 • 2016 ACR/ARHP Annual Meeting
Survival of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Zulema Rosales Rosado^1,2, Leticia León¹, Dalifer Freites Núñez², Judit Font Urgelles², Cynthia Milagros León Cárdenas², Cristina Vadillo Font², Luis Rodriguez Rodriguez¹, Juan A Jover Jover² and Lydia Abásolo Alcázar¹, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: After more than twenty years using Disease Modifying Drugs (DMARDs) is widely known their efficacy in the treatment of Rheumatoid Arthritis (RA) but it…
Abstract Number: 1775 • 2016 ACR/ARHP Annual Meeting
Smoking As a Predictor of Cutaneous Activity in Systemic Lupus Erythematosus
Shawn Kwatra¹, Michelle Petri² and Wei Fu³, ¹Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
ACR Abstract Authors: Shawn G. Kwatra1, Wei Fu2, Michelle Petri2 1Department of Dermatology, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD Title:…
Abstract Number: 1802 • 2016 ACR/ARHP Annual Meeting
Prevalence of CMV in the Ohio State University Lupus Population
Brian LaMoreaux¹, Alexa Meara², Holly Steigelman³, Juliette Yedimenko⁴, Wael N. Jarjour⁵ and Stacy P. Ardoin⁶, ¹Rheumatology, Fellow, Columbus, OH, ²Internal Medicine/Rheumatology, The Ohio State University, Columbus, OH, ³The Ohio State University, Columbus, OH, ⁴S2056, The Ohio State University, Columbus, OH, ⁵Department of Rheumatology/Medicine, Ohio State University, Columbus, OH, ⁶Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH
Background/Purpose: Systemic Lupus Erythematous (SLE) is a clinically variable autoimmune disease occurring predominantly in women of childbearing age. SLE treatment can range from close clinical…
Abstract Number: 2213 • 2016 ACR/ARHP Annual Meeting
The Four Stages of Fibromyalgia: Potential for More Precise Treatment Approaches
Mark Gostine¹, Fred Davis¹, Bradley Roberts², Rebecca Risko², Joseph C Cappelleri³, Andrew Clair⁴ and Alesia Sadosky⁵, ¹Michigan Pain Consultants, PC, Grand Rapids, MI, ²ProCare Systems, Inc., Grand Rapids, MI, ³Statistics, Pfizer Inc, New London, CT, ⁴Pfizer, New York, NY, ⁵Pfizer Inc,, New York, NY
Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain and tenderness making it difficult to manage. Accounting for FM heterogeneity might elicit an improvement in…
Abstract Number: 2318 • 2016 ACR/ARHP Annual Meeting
Real World Use of the Myositis Autoantibody Panel
Jason Weiner¹, Ryan Jessee², Robert T. Keenan³, Michael Datto⁴ and Lisa Criscione-Schreiber⁵, ¹Division of Rheumatology, Duke University, Durham, NC, ²Division of Internal Medicine, Duke University, Durham, NC, ³Rheumatology, Duke University, Durham, NC, ⁴Division of Pathology, Duke University, Durham, NC, ⁵Division of Rheumatology, Department of Medicine, Duke University, Durham, NC
Background/Purpose: The identification of myositis specific and associated autoantibodies occurring in idiopathic inflammatory myopathies (IIMs) has improved classification and prognosis determinations. With commercial availability, these…
Abstract Number: 2658 • 2016 ACR/ARHP Annual Meeting
Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Rheumatoid Arthritis
Zulema Rosales Rosado^1,2, Judit Font Urgelles¹, Dalifer Freites Núñez¹, Cynthia Milagros León Cárdenas¹, Cristina Lajas Petisco¹, Leticia Leon², Luis Rodriguez Rodriguez², Juan A Jover Jover¹ and Lydia Abásolo Alcázar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: There is a high risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. After more…
Abstract Number: 2686 • 2016 ACR/ARHP Annual Meeting
Objective Improvement in Fatigue Scores for Primary Sjögren’s Patients Receiving a Tailored Multidisciplinary Fatigue Intervention in a Generic Fatigue Clinic
Katie Hackett^1,2, Robert Forder³, Dennis W Lendrem⁴, Ben Hargreaves⁵, Victoria Strassheim^1,3, Zoe Gotts³, Vincent Deary^1,6, Wan-Fai Ng^7,8 and Julia Newton^1,3, ¹CRESTA Fatigue Clinic, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ³Newcastle University, Newcastle upon Tyne, United Kingdom, ⁴Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁵Musculoskeletal Directorate, Newcastle upon Tyne NHS Foundation Trust, Newcastle, United Kingdom, ⁶School of Health Psychology, Northumbia University, Newcastle upon Tyne, United Kingdom, ⁷Musculoskeletal Research Group Institute of Cellular Medicine, Newcastle University, Newcastle University, Newcastle, England, ⁸Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
Background/Purpose: Primary Sjögren’s syndrome (PSS) is an autoimmune disease which targets secretary glands resulting in dry eyes and mouth. Approximately 70% of PSS patients experience…
Abstract Number: 81 • 2016 ACR/ARHP Annual Meeting
Understanding the Importance of a Patient’s Role in the Management of RA: Physician- and Patient-Based Survey
Ara Dikranian¹, James Galloway², Joern Kekow³, Cristiano A.F Zerbini⁴, Maria de la Vega⁵, Gavin Lee⁶, Anna Maniccia⁷, Eustratios Bananis⁸, Dario Ponce de Leon⁹ and Allan Gibofsky¹⁰, ¹San Diego Arthritis Medical Clinic, San Diego, CA, ²King's College, and King´s College Hospital, London, United Kingdom, ³University of Magdeburg, Clinic of Rheumatology, Magdeburg, Germany, ⁴Centro Paulista de Investigação Clinica, São Paulo, Brazil, ⁵CEIM Investigaciones Médicas, Buenos Aires, Argentina, ⁶Hong Kong Sanatorium & Hospital, Hong Kong SAR, China, ⁷Pfizer Inc, New York, NY, ⁸Pfizer Inc, Collegeville, PA, ⁹Pfizer Inc, Lima, Peru, ¹⁰Rheumatology, Weill Cornell Medicine, and Hospital for Special Surgery, New York, NY
Background/Purpose: RA is a chronic, debilitating condition for which there is no cure. To identify and better understand the perspectives of both healthcare providers (HCPs)…
Abstract Number: 3138 • 2016 ACR/ARHP Annual Meeting
Sustained Improvement in Follow-up of Hypertension in Rheumatology Patients: Results of an Intervention Sustainability Assessment
Edmond Ramly^1,2, Daniel Panyard³, Diane Lauver⁴, Emmanuel Sampene⁵, Zhanhai Li⁵, Heather Johnson⁶, Patrick McBride⁶, Kristin Steffen Lewicki⁷ and Christie M. Bartels⁸, ¹Industrial and Systems Engineering, University of Wisconsin-Madison College of Engineering, Madison, WI, ²Department of Medicine, University of Wisconsin-Madison, Madison, WI, ³Population Health, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴University of Wisconsin-Madison School of Nursing, Madison, WI, ⁵Biostatistics, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁷Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁸Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Hypertension (HTN) is the most prevalent comorbid cardiovascular disease (CVD) risk factor among adults with rheumatic conditions. However, we previously found that high blood…
Abstract Number: 90 • 2016 ACR/ARHP Annual Meeting
Impacts of Anti-TNF Treatment on Improvement in Work Place and Household Productivity in Patients with Psoriatic Arthritis
Omer Karadag¹, Ediz Dalkilic², Ahmet Mesut Onat³, Orhan Kucuksahin⁴, Timucin Kasifoglu⁵, Bunyamin Kisacik⁶, Omer Nuri Pamuk⁷, Neslihan Yilmaz⁸, Suleyman Serdar Koca⁹, Veli Yazisiz¹⁰, Pinar Talu Ocakci¹¹, Mehmet Sayarlioglu¹², Ender Terzioglu¹³, Sukran Erten^14,15, Mustafa Ferhat Oksuz¹⁶ and Umut Kalyoncu¹, ¹Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Department of Rhematology, Uludag University Faculty of Medicine, Bursa, Turkey, ³Department Of Internal Medicine, Division of Rheumatology, Gaziantep University, Gaziantep University,Division of Rheumatology, Gaziantep, Turkey, ⁴Rheumatology, Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey, ⁵Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey, ⁶Rheumatology Department, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁷Rheumatology, Trakya University Faculty of Medicine, Edirne, Turkey, ⁸Department of Rheumatology, Bilim University Faculty of Medicine, Istanbul, Turkey, ⁹Department of Rheumatology Faculty of Medicine Firat University, Elazig, Turkey, ¹⁰Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, ¹¹Rheumatology, İzmir University Faculty of Medicine, izmir, Turkey, ¹²Rheumatology, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey, ¹³Division of Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, ¹⁴Rheumatology, Ataturk Training and Research Hospital, Ankara, Turkey, ¹⁵Rheumatology, Yildirim Beyazit University Faculty Of Medicine, Ankara, Turkey, ¹⁶Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey
Background/Purpose: Psoriatic arthritis (PsA) is a unique inflammatory arthritis that affects the skin, nails, and the joints. Most of the patients consider PsA to have…
Abstract Number: 3150 • 2016 ACR/ARHP Annual Meeting
The Initial Dose of Methotrexate per Weight Is Determinant of Disease Activity and Early DAS28 Remission in DMARD-Naive Early Rheumatoid Arthritis Patients Receiving Usual Care
Tuomas Rannio¹, Juha Asikainen², Pekka Hannonen², Timo Yli-Kerttula³, Päivi Ekman⁴, Laura Kuusalo⁵, Laura Pirilä⁶, Markku Mali⁷, Marja Puurtinen-Vilkki⁷, Satu Kortelainen⁷, Johanna Paltta⁶, Kirsi Taimen⁷, Markku J. Kauppi⁸, Kari Laiho⁹, Satu Nyrhinen⁹, Heidi Mäkinen¹⁰, Pia Isomäki¹⁰, Terhi Uotila¹⁰, Kalle Aaltonen¹¹, Hannu Kautiainen¹² and Tuulikki Sokka-Isler¹, ¹Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²Jyvaskyla Central Hospital, Jyväskylä, Finland, ³Sairaalantie 3, Satakunta Central Hospital, Rauma, Finland, ⁴Satakunta Central Hospital, Rauma, Finland, ⁵Rheumatology, Turku University Central Hospital, Turku, Finland, ⁶Turku University Hospital, Turku, Finland, ⁷Turku University Central Hospital, Turku, Finland, ⁸Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁹Päijät-Häme Central Hospital, Lahti, Finland, ¹⁰Tampere University Hospital, Tampere, Finland, ¹¹Helsinki University, Helsinki, Finland, ¹²Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Background/Purpose: Methotrexate (MTX) is considered as the anchor disease modifying antirheumatic drug (DMARD) in treatment of rheumatoid arthritis (RA). However, there is no advice…
Abstract Number: 267 • 2016 ACR/ARHP Annual Meeting
Diffuse Idiopathic Skeletal Hyperostosis: Can We Identify Different Clinicoradiological Patterns?
Teresa Clavaguera¹, Ramon Valls² and Mari Carmen Rodriguez-Jimeno², ¹Unitat de Reumatologia, Hospital de Palamós, Girona, Spain, ²rheumatology, Hospital de Palamós, Palamós, Spain
Background/Purpose: Diffuse Idiopathic Skeletal Hyperostosis (DISH) was described based on vertebral radiological signs (Resnick). Subsequently, Utsinger presented other criteria that add extraspinal involvement that allowed…
Abstract Number: 3211 • 2016 ACR/ARHP Annual Meeting
Early Radiological Progression in Rheumatoid Arthritis Leads to More Long-Term Joint Damage in Daily Clinical Practice; Six Year Radiological Outcomes of a Strict Treat-to-Target Cohort in the Netherlands
Letty G.A. Versteeg¹, Laura M.M. Steunebrink¹, Ina H. Kuper¹, Harald E. Vonkeman², Peter M. ten Klooster³, Arie E. van der Bijl⁴ and Mart A.F.J. van de Laar⁵, ¹Rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ²koningsplein, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ³Pcgr, University of Twente, Enschede, Netherlands, ⁴Isala Klinieken, Zwolle, Netherlands, ⁵Rheumatology, Arthritis Centre Twente, Medisch Spectrum Twente and University Twente, Enschede, Netherlands
Background/Purpose: Implementation of treat-to-target (T2T) in Rheumatoid Arthritis (RA) leads to limited radiological damage during follow-up of 3 years. Questions are whether these results are…
Abstract Number: 547 • 2016 ACR/ARHP Annual Meeting
Concordance Between Ultrasound Joint Synovitis and Clinical Joint Assessments By Patients or Physicians in Rheumatoid Arthritis
Ayako Hirata¹, Takehisa Ogura¹, Sayaka Takenaka¹, Hideki Ito², Yuki Fujisawa¹, Kennosuke Mizushina¹, Munetsugu Imamura¹, Norihide Hayashi² and Hideto Kameda¹, ¹Department of Rheumatology, Toho University Ohashi Medical Center, Tokyo, Japan, ²Toho University Ohashi Medical Center, Tokyo, Japan
Background/Purpose: Ultrasonography (US) has been prevalently used as a valid and objective modality for joint examination in patients with rheumatoid arthritis (RA). This study aimed…
Abstract Number: 1655 • 2015 ACR/ARHP Annual Meeting
Effectiveness of Monotherapy in Rheumatoid Arthritis (RA) Patients Initiating a Tumor Necrosis Factor Inhibitor (TNFi) Vs a Non-TNFi in a Large US Commercial and Medicare Advantage Plan
Benjamin Chastek¹, Jeffrey R. Curtis², Laura K. Becker³, George J. Joseph⁴ and Chieh-I Chen⁵, ¹Optum Insight, Eden Prairie, MN, ²University of Alabama at Birmingham, Birmingham, AL, ³Optum, Eden Prairie, MN, ⁴Global Health Economics & Outcomes Research (HEOR), Sanofi, Bridgewater, NJ, ⁵Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Monotherapy accounts for approximately 30% of biologic disease-modifying anti-rheumatic drug (DMARD) use in RA (Emery P et al. Ann Rheum Dis 2013;72:1897-904). A validated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].